Floatz logo

LISPRO-PH20 COMPONENT RHUPH20

Clear Cell Renal Cell Carcinoma

Bristol-Myers Squibbprotein_peptidePhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

115 Active assets in the Clear Cell Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
gw786034
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
Girentuximab
Massachusetts General Hospital
Phase 3BB
CLOSTRIDIUM BUTYRICUM MIYAIRI 588
City of Hope Medical Center
Phase 3BB
gw786034
Academic and Community Cancer Research United
Phase 4BB
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Regeneron Pharmaceuticals
Phase 2BB

View all 50 →

Same molecule, other indications

LISPRO-PH20 COMPONENT RHUPH20 is also rated in:

hereditary angioedemaDormant
B
Indicative ·
62 / 100
View asset →
smoldering plasma cell myelomaDormant
B
Indicative ·
59 / 100
View asset →
melanomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →